Artrya Expands U.S. Commercial Footprint with Salix® Rollout
Artrya Limited (ASX: AYA) has achieved another commercial milestone with its AI-powered Salix® platform going live at Northeast Georgia Health System (NGHS), marking the beginning of revenue generation from its second U.S. clinical customer. The platform is now operational at the first of NGHS’s five hospitals, with expansion across the remaining sites planned in the near term. Salix® Coronary Anatomy and Salix® Coronary Plaque are being incorporated into routine clinical workflows, enabling Artrya to earn recurring subscription income alongside fee-per-scan revenue for plaque assessments. The company also expects to activate its Coronary Flow module once U.S. regulatory clearance is obtained, creating an additional source of transaction-based revenue.
The deployment strengthens Artrya’s presence in the U.S. healthcare market and highlights growing adoption of AI-assisted diagnostic tools for coronary artery disease. Clinicians at the Georgia Heart Institute, which serves more than 100,000 patients annually, are already using Salix® outputs as part of routine patient assessments. Management indicated that commercial rollouts with its remaining U.S. foundation partners are progressing, positioning the company for broader revenue growth. Artrya continues to focus on improving the speed and accuracy of coronary CT scan interpretation through its AI-driven platform while expanding its international commercial footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Artrya Expands U.S. Commercial Footprint with Salix® Rollout
Artrya Limited (ASX: AYA) has achieved another commercial milestone with its AI-powered Salix® platform going live at Northeast Georgia Health System (NGHS), marking the beginning of revenue generation from its second U.S. clinical customer. The platform is now operational at the first of NGHS’s five hospitals, with expansion across the remaining sites planned in the near term. Salix® Coronary Anatomy and Salix® Coronary Plaque are being incorporated into routine clinical workflows, enabling Artrya to earn recurring subscription income alongside fee-per-scan revenue for plaque assessments. The company also expects to activate its Coronary Flow module once U.S. regulatory clearance is obtained, creating an additional source of transaction-based revenue.
The deployment strengthens Artrya’s presence in the U.S. healthcare market and highlights growing adoption of AI-assisted diagnostic tools for coronary artery disease. Clinicians at the Georgia Heart Institute, which serves more than 100,000 patients annually, are already using Salix® outputs as part of routine patient assessments. Management indicated that commercial rollouts with its remaining U.S. foundation partners are progressing, positioning the company for broader revenue growth. Artrya continues to focus on improving the speed and accuracy of coronary CT scan interpretation through its AI-driven platform while expanding its international commercial footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au